

1-800-533-1710

PATIENT NAME			PATIENT NU	MBER		AGE	SEX	ACCESSION #
TESTING, 91402						50	F	W3715057
ORDERING PHYSICIAN			CLIENT ORD	CLIENT ORDER #				
					•			LIAISONS
COLLECTION	RECEIVED		REPORT PR	INTED	SPECIMEN INFORMA	TION		
04/30/10 01:22 P	04/30/10 ()1:22 P	05/03/10	08:58 A	DATE OF BIRTH: 6	6/25/1959)	
DATE TIME	DATE	TIME	DATE	TIME				
Test Client								
Attn: Mayo Liaisons								
200 First Street SW								
Rochester, MN 55905								
507-284-8202								
	HI							

	HI				
TEST REQUESTED	LO			REF RANGE	PERFORM SITE *
HCV FibroSURE					
HCV FibroSURE Results:					REF
Fibrosis Score	н	0.80		0.00 - 0.21	REF
Fibrosis Stage		0.00		0.00 - 0.21	REF
F4 - Cirrhosis					INEI
Necroinflammat Activity	н	0.71		0.00 - 0.17	REF
Score	••	•		0.00	
Necroinflammat Activity					REF
Grade					
A3-Severe activi	itv				
Analysis:	-				REF
Alpha 2	Н	346	mg/dL	110 - 276	REF
Macroglobulins, Qn			•		
Haptoglobin		41	mg/dL	34 - 200	REF
Apolipoprotein A-1		131	mg/dL	110 - 205	REF
Bilirubin, Total		0.7	mg/dL		REF
Newborns	, term	and near term	<u>.</u>		
24 hour	rs old:		0.0 - 8.0		
48 hour	rs old:		0.0 - 13.2		
72 hour	rs old:		0.0 - 15.6		
96 hour	rs to 1	month old:	0.0 - 16.6		
Children	1 mont	h and older a	nd		
Adults:			0.0 - 1.2		
GGT	Н	66	IU/L	0 - 60	REF
ALT (SGPT)	Н	91	IU/L	0 - 40	REF
Interpretations					

Interpretations:

Quantitative results of 6 biochemical tests are analyzed using a computational algorithm to provide a quantitative surrogate marker (0.0-1.0) for liver fibrosis (METAVIR F0-F4) and for necroinflammatory activity (METAVIR A0-A3). Fibrosis Scoring:

* Perform Site Legend on last page of report

PATIENT NAME	ORDER STATUS	COLLECTION DATE AND TIME
TESTING, 91402	Final	04/30/10 01:22 P

PERFORM SITE *

REF RANGE



1-800-533-1710

PATIENT NAME			PATIENT NU	MBER		AGE	SEX	ACCESSION #
TESTING, 91402						50	F	W3715057
ORDERING PHYSICIAN			CLIENT ORD	ER#				ACCOUNT #
COLLECTION	RECEIVED		REPORT PR		SPECIMEN INFORMA			
04/30/10 01:22 P	04/30/10		05/03/10	08:58 A	DATE OF BIRTH:	6/25/1959	9	
DATE TIME	DATE	TIME	DATE	TIME				
Test Client								
Attn: Mayo Liaisons								
200 First Street SW								
Rochester, MN 55905								
507-284-8202								
	HI				<u> </u>			

LO

<0.21 = Stage F0 - No fibrosis

0.21 - 0.27 = Stage F0 - F1

0.27 - 0.31 = Stage F1 - Portal fibrosis

0.31 - 0.48 = Stage F1 - F2

0.48 - 0.58 = Stage F2 - Bridging fibrosis with few septa

0.58 - 0.72 = Stage F3 - Bridging fibrosis with many septa

0.72 - 0.74 = Stage F3 - F4

>0.74 = Stage F4 - Cirrhosis

Necroinflamm Activity Scoring:

<0.17 = Grade A0 - No Activity

0.17 - 0.29 = Grade A0 - A1

0.29 - 0.36 = Grade A1 - Minimal activity

0.36 - 0.52 = Grade A1 - A2

0.52 - 0.60 = Grade A2 - Moderate activity

0.60 - 0.62 = Grade A2 - A3

>0.62 = Grade A3 - Severe activity

Limitations:

TEST REQUESTED

The negative predictive value of a Fibrotest score <0.31 (absence of clinically significant fibrosis) was 85% when compared to liver biopsy in 1,270 HCV infected patients with a 38% prevalence of significant liver fibrosis (F2, 3 or 4). The positive predictive value of a Fibrotest score >0.48 (F2, 3, 4) was 61% in that same patient cohort. HCV FibroSURE is not recommended in patients with Gilbert Disease, acute hemolysis (e.g. HCV ribavirin therapy mediated hemolysis), acute hepatitis of the liver, extrahepatic cholestasis, transplant patients, and/or renal insufficiency patients. Any of these clinical situations may lead to inaccurate quantitative predictions of fibrosis and necroinflammatory activity in the liver. Comment:

The performance characteristics of this test have been

* Perform Site Legend on last page of report

PATIENT NAME	ORDER STATUS	COLLECTION DATE AND TIME
TESTING, 91402	Final	04/30/10 01:22 P



1-800-533-1710

PATIENT NAME TESTING, 91402		PATIENT NU	MBER		AGE 50	SEX F	ACCESSION # W3715057
ORDERING PHYSICIAN		CLIENT ORD	ER#		•		ACCOUNT # LIAISONS
COLLECTION 04/30/10 01:22 P DATE TIME Test Client Attn: Mayo Liaisons 200 First Street SW Rochester, MN 55905 507-284-8202	RECEIVED 04/30/10 0 DATE	REPORT PR 05/03/10 DATE	08:58 A TIME	SPECIMEN INFORMA DATE OF BIRTH:)	

н

TEST REQUESTED

LO

REF RANGE PERFORM SITE *

determined by LabCorp. This test has not been cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not currently required. LabCorp is regulated under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and is certified to perform high complexity testing. Results and Interpretation Provided by:
LabCorp RTP 1912 Alexander Drive Research Triangle Park, NC 27709 Analysis-Test Performed by:
LabCorp Burlington 1447 York Court Burlington, NC 27215-2230

* PERFORMING SITE

PATIENT NAME	ORDER STATUS	COLLECTION DATE AND TIME
TESTING, 91402	Final	04/30/10 01:22 P